Literature DB >> 30284179

The association between treatment appropriateness according to EUCAST and CLSI breakpoints and mortality among patients with candidemia: a retrospective observational study.

Nesrin Ghanem-Zoubi1, Danny Zorbavel2, Johad Khoury3, Yuval Geffen4, Majd Qasum5, Svetlana Predescu4, Mical Paul6.   

Abstract

To evaluate the association between appropriate antifungal treatment and mortality among patients with candidemia using different breakpoint definitions. In a retrospective study, we included all adults with candidemia in a tertiary center between 2009 and 2015. We defined three versions of appropriate (covering) antifungal treatment, according to Clinical and Laboratory Standards Institute (CLSI) 2008, CLSI 2012, and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (2017 update) breakpoints. For empiric treatment, we evaluated the association with 30-day mortality. For definitive treatment, we evaluated the association with 90-day mortality among patients surviving the first week after candidemia onset. Adjusted odds ratios (OR) from a bivariate logistic regression with 95% confidence intervals are reported. We identified 302 patients with 308 separate candidemia episodes. The crude 30-day mortality was 55% (168/308). Resistance to anidulafungin increased from 3.5 to 51.6% and to fluconazole from 15.2 to 44.1%, when applying CLSI 2008 and EUCAST definitions, respectively. Appropriate empirical treatment was significantly associated with lower 30-day mortality using the CLSI 2008 definitions, adjusted OR 0.56 (0.33-0.96). The associations were similar, though not statistically significant for EUCAST, 0.58 (0.33-1.00), and CLSI 2012, OR 0.62 (0.37-1.04). Appropriate definitive treatment according to CLSI 2012 and EUCAST was independently associated with lower 90-day mortality, ORs 0.31 (0.13-0.75) and 0.44 (0.23-0.8), respectively. With CLSI 2008, the association was similar but not statistically significant, OR 0.4 (0.11-1.41), with few isolates classified as resistant. Considering the major shift in resistance prevalence when applying CLSI 2008, CLSI 2012, and EUCAST breakpoint definitions, no major differences were observed in their association with mortality.

Entities:  

Keywords:  Antifungal; Breakpoints; CLSI; Candidemia; EUCAST; Mortality

Mesh:

Substances:

Year:  2018        PMID: 30284179     DOI: 10.1007/s10096-018-3389-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  26 in total

1.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

2.  Interlaboratory variability of Caspofungin MICs for Candida spp. Using CLSI and EUCAST methods: should the clinical laboratory be testing this agent?

Authors:  A Espinel-Ingroff; M C Arendrup; M A Pfaller; L X Bonfietti; B Bustamante; E Canton; E Chryssanthou; M Cuenca-Estrella; E Dannaoui; A Fothergill; J Fuller; P Gaustad; G M Gonzalez; J Guarro; C Lass-Flörl; S R Lockhart; J F Meis; C B Moore; L Ostrosky-Zeichner; T Pelaez; S R B S Pukinskas; G St-Germain; M W Szeszs; J Turnidge
Journal:  Antimicrob Agents Chemother       Date:  2013-09-09       Impact factor: 5.191

3.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

4.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

5.  A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality.

Authors:  Matteo Bassetti; Elda Righi; Filippo Ansaldi; Maria Merelli; Cecilia Trucchi; Trucchi Cecilia; Gennaro De Pascale; Ana Diaz-Martin; Roberto Luzzati; Chiara Rosin; Leonel Lagunes; Enrico Maria Trecarichi; Maurizio Sanguinetti; Brunella Posteraro; Jose Garnacho-Montero; Assunta Sartor; Jordi Rello; Giorgio Della Rocca; Massimo Antonelli; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2014-05-08       Impact factor: 17.440

6.  Anidulafungin versus fluconazole for invasive candidiasis.

Authors:  Annette C Reboli; Coleman Rotstein; Peter G Pappas; Stanley W Chapman; Daniel H Kett; Deepali Kumar; Robert Betts; Michele Wible; Beth P Goldstein; Jennifer Schranz; David S Krause; Thomas J Walsh
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

7.  FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.

Authors:  Nicholas D Beyda; Julie John; Abdullah Kilic; Mohammad J Alam; Todd M Lasco; Kevin W Garey
Journal:  Clin Infect Dis       Date:  2014-05-30       Impact factor: 9.079

8.  Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.

Authors:  Laurent Tadec; Jean-Philippe Talarmin; Thomas Gastinne; Cédric Bretonnière; Michel Miegeville; Patrice Le Pape; Florent Morio
Journal:  Mycoses       Date:  2016-01-25       Impact factor: 4.377

9.  Comparative Analysis of Disc Diffusion and E-test with Broth Micro-dilution for Susceptibility Testing of Clinical Candida Isolates Against Amphotericin B, Fluconazole, Voriconazole and Caspofungin.

Authors:  Deepak Kumar; Sayan Bhattacharyya; Prashant Gupta; Gopa Banerjee; Mastan Singh
Journal:  J Clin Diagn Res       Date:  2015-11-01

10.  EUCAST technical note on Candida and micafungin, anidulafungin and fluconazole.

Authors:  Maiken Cavling Arendrup; Manuel Cuenca-Estrella; Cornelia Lass-Flörl; William W Hope
Journal:  Mycoses       Date:  2014-01-13       Impact factor: 4.377

View more
  2 in total

1.  Association between Following the ESCMID Guidelines for the Management of Candidemia and Mortality: A Retrospective Cohort Study.

Authors:  Charles Maurille; Julie Bonhomme; Anaïs R Briant; Jean-Jacques Parienti; Renaud Verdon; Anna Lucie Fournier
Journal:  J Fungi (Basel)       Date:  2022-05-23

2.  Risk Factors for Mortality in Colombian Patients with Candidemia.

Authors:  Jorge Alberto Cortés; Anita María Montañez; Ana María Carreño-Gutiérrez; Patricia Reyes; Carlos Hernando Gómez; Angela Pescador; Beatriz Ariza; Fernando Rosso
Journal:  J Fungi (Basel)       Date:  2021-05-31
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.